Bladder Cancer Weekly

June 29, 2026

Videos

Peer-to-Peer Clinical Conversations

More Than a Diagnosis: Global Survey Exposes the Emotional and Physical Toll of Bladder Cancer Treatment - Gina Carithers

Gina Carithers

Gina Carithers reflects on the Bladder Burden Survey and patient advocacy, discussing her role moderating the panel held before AUA 2026.

CORE-008 CX Early Efficacy and Tolerability Data - Aaron Berger

Aaron Berger

Aaron Berger presents CORE-008 CX arm data.

Beyond the Abstracts

Detection of Bladder Cancer in Patients with Microscopic Hematuria Using Oncuria-Detect: Results of a Prospective, Multicenter International Study - Beyond the Abstract

Modulating the PPARγ Pathway Upregulates NECTIN4 and Enhances Chimeric Antigen Receptor (CAR) T Cell Therapy in Bladder Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized MIBC Patients: SASAN-SPARING Trial

ASCO 2026: Bulumtatug Fuvedotin + Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Follow-up Results from a Phase 1b/2 Study

AUA 2026: Trials in Progress: In-home iNtraVesIcal ThErapy (INVITE) Study – A Phase Ib/II, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients’ Homes

AUA 2026: Duration of Response to UGN-102 by Age at Baseline Across 3 Clinical Trials in Patients with Recurrent Low Grade Intermediate Risk Bladder Cancer

SES AUA 2026: Topline Results from BOND-003 Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-unresponsive NMIBC 

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

BCG Induces PD-1 Upregulation on Circulating CD8+ T Cells and IL-6 and IL-8 Secretion In Vitro.

Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.

Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.

Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis.

Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged ≤45: A Retrospective Matched Cohort Study.

A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder.

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.

CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.

Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC